ALSO NOTED: Novartis faces development bottleneck; Bayer lowers 2008 expectations;and much more...

> Five years ago Novartis set out to speed drug development, hoping to quickly advance discoveries in the lab to approval. Now the project has been so successful that the company now has a Phase II/III bottleneck. Blog

> Call it Bad News Bayer. The German company reported a whopping 78 percent drop in profits for the fourth quarter and forecast 2008 sales growth at its lowest level in years. Though 2007 full-year results were actually quite good--sales grew 11.8 percent--shares are down 15 percent since January 1 on a series of disappointing news. Report

> It's a grim trifecta of heparin news today. Regulators say they've now found 21 deaths that may be linked to Baxter's recalled blood thinner. FDA inspectors uncovered quality-control problems at the Chinese plant where crude heparin was processed for Baxter's supplier. And Baxter widened its recall to include not just its multidose heparin vials but single-dose packaging and diluted heparin. Report

> The FDA's pleas for more money are gaining attention in Congress. Report

> Victory for Amgen--and maybe for Roche, too. The California drug maker persuaded a judge to temporarily ban Roche's competing anemia drug Mircera in the U.S. Report

And Finally... A CDC study confirms what many of us already know: American's aren't getting enough sleep. Report

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.